Archive | Of Interest

NCI awards $11 million grant to NYU Langone to develop immunotherapy biomarkers

NCI awarded a 5-year, $11 million grant to NYU Langone Health’s Ronald O. Perelman department of dermatology to develop biomarkers that can predict whether immunotherapy will be effective for specific patients.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Targeted Drug Combination Can Have Long-Lasting Results for Some With BRAF-Mutated Melanoma

For about half of patients with advanced melanoma, there is only one treatment choice: immunotherapy. But for those whose late-stage melanoma expresses a BRAF gene mutation, there’s another option – combinations of targeted drugs.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Novel nano-vaccine for melanoma

Researchers at Tel Aviv University have developed a novel nano-vaccine for melanoma, the most aggressive type of skin cancer.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Melanoma Checkpoint Therapy More Potent in Combination with Nanovaccine

Dissonant signaling, which can deafen the immune system to cancer, can be replaced by something more harmonious—and therapeutic—if immunotherapies silence a note, sound another, or play an especially resonant chord.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest